A team of Queensland medical researchers are sharing 80 years of innovation at an international conference in the United States.
The QIMR Berghofer delegation, which includes renowned scientists and business development leaders, is showcasing the medical research institute’s pioneering research and commercial capabilities at BIO2025 in Boston.
QIMR Berghofer COO Stephen Weller said as the Brisbane-based medical research institute celebrated it 80th anniversary, its presence at BIO2025 highlighted an ongoing commitment to translating cutting-edge discoveries into real-world solutions for cancer, infectious diseases, brain and mental health, and population health.
Dr Weller said BIO2025 was one of the world’s largest gatherings for the biotechnology sector, bringing together over 20,000 industry leaders, researchers, and innovators from more than 70 countries.
He said a highlight for the Queensland team was having Associate Professor Michelle Wykes, the Chief Scientific Officer of QIMR Berghofer spin-out company Fovero Therapeutics, present on innovative immune pathway discoveries that underpinned new therapies for cancer and autoimmune diseases.
“BIO2025 is a unique opportunity for QIMR Berghofer to connect with international leaders and showcase the breadth of our research and innovation.
“This year, as QIMR Berghofer marks eight decades of scientific achievement, the Institute is leveraging BIO2025’s dynamic networking and partnering platform to forge new collaborations, expand its global impact, and attract investment for its research pipeline.”
Dr Weller said the Institute’s contract research and commercialisation teams were also exploring partnership opportunities in drug development, clinical trials, and advanced therapeutics.
